Medicare & MedicaidBack to stories →
← Back to stories

AB 1682 adds qualifying scalp cooling coverage

AB 1682 adds prescribed FDA-cleared scalp cooling coverage for qualifying large-group 2027 contracts and conditionally for Medi-Cal.

What happened

California approved and filed AB 1682 on September 27. The enacted commercial provisions apply to large-group plan contracts and insurance policies issued, amended or renewed on or after January 1, 2027. They require coverage for scalp cooling prescribed by a health care provider to reduce the incidence or severity of hair loss before, during or after treatment with alopecia-inducing chemotherapy. Copayments, coinsurance and deductibles remain permissible, but may be no less favorable than those for oncology supportive care under the same coverage. Specialized plans and policies are excluded from these commercial provisions.

The covered scalp-cooling definition requires an FDA-cleared device or system and expressly excludes non-cleared cold caps or products regardless of their marketing label. Medi-Cal managed care contracts fall under the separate WIC 14132.65 provision instead of the large-group mandate. That provision treats prescribed scalp cooling as a covered benefit subject to medical necessity and utilization controls, but implementation is conditioned on necessary federal approvals and available federal financial participation that is not jeopardized. DHCS may implement through letters, bulletins or similar instructions. As of October 4, the chaptered language supports preparation and monitoring of those conditions, rather than assuming every chemotherapy patient or product is already payable.

Scope and timing

Authority status
Final
Applicability
Potentially applicable
Audience
Health systems, Provider networks
Jurisdiction
California
Affected functions
Managed Care, Revenue Cycle, IT, Clinical Operations, Compliance
Responsible owner
Managed Care
Recorded date
2027-01-01
Date type
implementation

Why it matters

Oncology benefit and authorization rules need to identify eligible devices, contracts and cost sharing while distinguishing the conditional Medi-Cal pathway.

Implementation playbook

  1. Confirm affected benefits, contracts, statutory conditions and applicable dates. Managed Care · Due 2026-10-18
  2. Confirm affected large-group benefits, medical necessity and coding; track Medi-Cal approvals and guidance rather than assuming immediate universal reimbursement. Managed Care · Due 2027-01-01
  3. Test revised workflows and member or provider communications before implementation. Compliance · Due 2027-01-01

Sources

Complete edition and supplemental material

This finding in the complete approved report →

Regulatory horizons, CIA trends and implementation trackers remain in the full report.

Read the entire Medicare & Medicaid report →

← Return to stories

Privacy preferences

Where enabled for this site, Cloudflare Web Analytics can send page-use and performance measurements to Cloudflare. This panel provides information and does not turn analytics on or off.

This panel stores no tracking choice and does not change your tool saves, screening, resets, reports or exports. Other sites have separate settings.

Read Privacy & Cookies